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1. Abstract   
Background 
The incidence of melanoma is increasing worldwide. Recently, new treatment 
modalities changed the era in metastatic melanoma patients. However, there is still a 
group of patients who suffer from rapidly progressive disease and die shortly after 
being diagnosed with stage IV metastatic melanoma. Whether there are implications 
in genetic changes, clinical decision making or clinic-pathological characteristics in 
this group has to be elucidated. 
 
Objectives  
The aim of this master thesis is to analyze the group of patients with rapidly 
progressive lethal melanoma and to investigate their clinical characteristics and 
prognostic implications.  
 
Materials and Methods 
In this retrospective study, we analyzed 442 stage IV melanoma patients who have 
been treated at the Department of Dermatology, University Hospital Zurich from 
January 2008 until December 2014. The required information was gathered from the 
clinical electronic patient database (KISIM). 23 patients who died within the first 3 
months, after being diagnosed with stage IV disease, formed our study group. A 
control group is composed also of advanced melanoma patients who have the best 
overall survival during this period.  
 
Results  
There is no significant difference in mutation status and characteristics of the primary 
melanoma between the study group and the control group. The negative prognostic 
factors seem to be elevated LDH and S100 levels, the male gender as well as bone, 
brain and liver metastasis.  
 
Conclusion 
We identified a patient group with rapidly progressive melanoma. We could confirm 
that patients with rapidly progressive melanoma (male, patients with elevated 
LDH/S100 levels, patients with brain/bone/liver metastasis) have high tumor volume. 
Further immunohistochemical and molecular investigation needs to be done.  
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2. Abbreviations  
 
MM Malignant Melanoma 
IR Incidence Rate 
SR Survival Rate 
PFS Progression Free Survival 
OS Overall Survival 
CR Complete Response 
NF1 Neurofibromatosis 1 
PD Progressive Disease 
USZ University Hospital Zurich 
AJCC American Joint Committee on Cancer 
MRT Melanoma Registry Table 
SG Study Group 
CG Control Group 
DFS Disease Free Survival 
SSM Superficial Spreading Melanoma 
NMM Nodular Malignant Melanoma 
ALM Acral Lentiginous Melanoma 
SNLB Sentinel Lymph Node Biopsy 
LDH Lactate Dehydrogenase 
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3. Introduction  
3.1. Melanoma Epidemiology 
Malignant Melanoma (MM) is one of the most aggressive skin cancer, whose 
incidence is still increasing in many parts of the world, especially in light-skinned 
populations (1). This increase was observed over the last decades and is predicted 
to continue for at least two more (2). Switzerland has the highest incidence rate (IR) 
of newly developed MM per year in Europe (3). Although MM only represents 5% of 
all skin malignancies, it is responsible for the majority of lethal cases. Unlike its rising 
incidence, mortality has been stable since the 1980s in most parts of the world (2). 
This is mainly due to introduction of new treatment options, which resulted into 
survival rates (SR) improvement, new methods of early diagnostics as well as its 
diagnosis in very early stages (4, 5). 
Due to its rising incidence, MM represents a major public health issue. Augmented 
UV exposure causing DNA damage is one well-studied factor for genetic changes 
resulting in melanoma formation and as of now the only that can be affected (6). This 
rise is not only a result of an increased recreational exposure to solar UV radiation, 
but as well as to indoor tanning activities (5, 7). Changes in style-clothing, 
contemporary tanning, expanded outdoor activities, ozone depletion and longevity 
contribute to this augmented exposure (8). Furthermore, international holidays are 
more accessible nowadays.  
 
On the other hand, prevention is one of the major topics in the battle against cancer. 
According to questionnaires, 85% of Swiss adults use regular sun protection. 
Furthermore, women take sun protection more seriously than men do (89% versus 
79%). In fact, the younger generations protect themselves more often then the older 
ones. The level of education as well as the income also have an influence: people 
with a higher education and income protect themselves better (6).  
 
Since 2008 new treatment options changed the landscape of advanced melanoma 
and significantly improved not only progression free survival (PFS), but also overall 
survival (OS) (9, 10, 11, 12, 13, 14, 15, 16, 17). However, there is still a group of 
patients, who does not seem to profit from the new treatments. Over hundred BRAF 
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mutated patients with rapid disease progression under treatment with vemurafenib 
(BRAF-inhibitor) alone or combined with cobimetinib (MEK-inhibitor) were recently 
identified (18). Genomic differences between metastatic melanoma tumors from 
patients with complete response (CR) to therapy versus patients with progressive 
disease (PD) were suggested according to a recent data exploratory analysis. 
Patients with CR presented higher pre-existing immune response profile with 
enrichment of CD8 T effector cells, cytolytic T-cells, antigen presentation and NK 
cells, whereas patients with PD expressed more keratin genes (18).  
 
3.2. Pathogenesis of Melanoma 
In the last few years and with the introduction of next generations sequencing, a vast 
number of melanoma “driver” genes was identified (19).  
 
Approximately 80% of melanoma patients have genetic alterations in oncogenes and 
tumor suppressor genes, which regulate the mitogen activated protein kinase 
pathway (MAPK). This leads to a constitutive signaling trough RAS-RAF-MEK-ERK 
(Fig. 1) and eventually in alteration of cell proliferation and senescence (20) (21). The 
most common mutation is BRAF, which is harbored by approximately 50% of all 
melanomas, followed by NRAS, which is also mutated in nearly 30% of all melanoma 
patients (19, 22). Mutations in other pathways as WNT or PI3K are less common but 
also very important. 
 
Krauthammer et al. additionally identified new important mutations in melanoma, 
including neurofibromatosis 1 (NF1), the third most common mutated gene in 
melanoma after BRAF and NRAS. NF1, a negative regulator of RAS, leading to a 
higher RAS activation when possessing an inactivating mutation (19). NF1 
represents a key tumor suppressor, which is often lost in melanomas. The Cell 
Genome Atlas recently proposed a new genomic classification for cutaneous 
melanoma as: mutated BRAF, mutated NRAS, mutated NF1 and triple wild-type (23). 
This classification facilitates clinical decision-making based on targeted therapies.  
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Fig. 1: MAPK- and PI3K-Pathway (21). 
 
3.3. Metastatic Melanoma 
As soon as the tumor cells break through the basal membrane, then the disease 
becomes invasive into deeper dermis and subcutaneous tissue. The dissemination 
can either be hematogenous or through the lymphatic vessels.  
 
3.3.1. Loco Regional Metastasis 
Loco regional metastasis comprise of local recurrences, locoregional lymph node 
metastasis, satellites metastasis (which appear inside a radius of 2cm from the 
primary tumor) as well as skin or subcutaneous metastasis, which occur along the 
lymph pathways between the primary tumor and the regional lymph nodes (in transit 
metastasis). 
 
3.3.2. Distant Metastasis 
In general, neoplastic development progresses through several stages as tumor 
initiation, progression, invasion and then metastasis (24). To perambulate those 
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steps, malignant cells need to acquire certain carcinogenic features such as 
unlimited proliferation, evasion of cell intrinsic and environmental restrictions, 
attraction of a blood supply and the capacity to detach and distance itself from the 
original location. These features are prerequisites for the tumor initiation and 
progression (25). Further genetic alterations have to occur before malignant cells 
become invasive, enter the circulation and evade the immune system to colonize 
other organs (25). The fact, that melanocytes are naturally resistant to ultraviolet light 
and reactive oxygen species, is one reason why melanoma cells are particularly 
resistant to killing (24).  
 
Furthermore, it has been proposed that malignant melanoma cells have two gene 
expression signatures, which is either proliferative (upregulation of MITF, TYR and 
DCT) or invasive (upregulation of WNT5A, TGFβ and FGF2). The cells can switch 
from one signature to the other in response to microenvironmental changes 
(=phenotype switch). Recently, the SOX9-gene overexpression in malignant 
melanoma cells could be identified as an important gene in melanoma invasion (26). 
 
When the tumor cells spread beyond the loco regional lymph nodes, then the disease 
is defined as distant. 
 
3.4. Prognostic Factors 
Several factors, designating as prognostic factors, which implicate the outcome of 
melanoma patients, have been investigated over the years. In the following 
subchapters the main ones are listed.  
 
3.4.1. Patient-related 
3.4.1.1. Gender  
In a recently published Italian study (involving 3900 patients) Crocetti et al. showed 
that women who suffer from cutaneous melanoma have an improved 5-year disease 
specific survival compared to men (women = 87% vs. men = 80%, 95%-confidence 
interval: 86% – 89% and 78% – 82%, respectively). Survival did not seem to 
implicate with disease stages. The cause of this superiority remains still unknown 
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(27). Consistently, it has been suggested, that women have a better prognosis in 
every stage of the disease, due to lower risk of visceral metastasis and lymph node 
invasion (28). What could also contribute to a better survival is the postulation that 
women look better after their health and skin. On the other hand, another study 
showed that women have a higher risk to be diagnosed with melanoma (29). 
 
3.4.1.2. Age 
Until recently, age has been reported to be an independent prognostic factor for the 
outcome of melanoma patients (30, 31, 32). However, in 2013 Balch et al. reported 
that the patient’s age is a powerful and highly significant predictor of survival. They 
came to this result even after accounting for adverse prognostic features, e.g. 
anatomic site of the primary melanoma and patient’s gender. Furthermore, this study 
suggested that younger patients (<20 years) have a significant better survival than all 
other age groups (p < 0.0001). This seems paradoxical due to the fact that these 
patients had a primary tumor with slightly more aggressive characteristics and a 
higher incidence of sentinel lymph node micrometastasis than all other age groups. 
The lowest survival is observed in patients over 70 years (p < 0.0001) (33). In a large 
study with more than 17’000 patients, every 10-year increase in age was associated 
with a decrease in 5- and also 10-year survival rates (32) 
 
3.4.1.3. Localization  
Cutaneous melanoma appears more frequently on the back and limbs (especially the 
lower limb in women), followed by the head and neck, and then the anterior trunk (34, 
35). The typical sites for the primary melanoma in younger patients are trunk and 
limbs. In older patients, it mostly occurs on sun exposed skin areas as the head and 
neck. Patients who develop melanomas on the trunk have markedly higher nevus 
count, which is known to be another risk factor for melanoma, than those whose 
melanomas arise on sun-exposed sites (36).  
 
A correlation between anatomic location and prognosis has been postulated. 
Melanomas of the head, neck and trunk, have a poorer prognosis compared to 
melanomas on the extremities (37, 38, 39).  
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3.4.2. Histology 
3.4.2.1. Thickness 
The thickness of the primary tumor, known as Breslow index, and measured in 
millimeters from the granular layer to the deepest identifiable tumor manifestation, 
has significant prognostic implications (40). It is the most powerful independent 
prognostic variable in localized melanoma, followed by ulceration. In a study of over 
11’000 patients Balch et al. showed a highly significant decrease in 5- and 10-year 
survival rates as tumor thickness increased (41). The AJCC melanoma staging 
stratified the thickness in four categories for the T-staging: ≤1.0 mm, 1.01-2.0 mm, 
2.01-4.0 mm, >4 mm (32). 
 
3.4.2.2. Ulceration 
Already in 1953, Allen & Spitz described ulceration, defined as the absence of an 
intact epidermis, as another adverse prognostic factor (42). Balch et al. illustrated in 
1980 that patients with ulcerated melanoma had a poorer survival in comparison to 
non-ulcerated melanoma, even though other factors, such as gender and age, had 
been accounted for (43). Ulceration correlates highly with tumor thickness. It has 
been shown, that with the increased tumor thickness, also the incidence of ulceration 
rose (6-12.5% for thin, 63-72.5% for thick melanomas, p < 0.0001) (32, 43). 
However, in contrast to the thickness, ulceration remains an important prognostic 
factor even if nodal metastasis appear (stage III). It is the only feature of the primary 
tumor that indicates a adverse outcome in stage III (32). They came to the conclusion 
that “ulceration reflects a more aggressive and infiltrative character of melanoma 
than non-ulcerative lesions” (31). The incorporation of ulceration in the AJCC 
melanoma staging system took place in 2001 (32). 
 
3.4.3. Laboratory Parameters  
S100   
S100 is a protein, which plays a central role in the signal transduction of the cell cycle 
regulation. There are two subtypes of the S100 protein: S100A and S100B. S100B is 
only expressed in cells of the nervous system, cartilage cells, adipocytes and cells of 
melanocytic origin (44). Initial, it has been used as a serum marker for acute brain 
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damage. About 20 years ago S100B was first described as a serum marker for 
malignant melanoma (45). Nowadays S100B-diagnostics is widely accepted as the 
main tumor marker in malignant melanoma used in the clinic (46). The concentration 
of S100B in the serum is strongly depending on the tumor burden. When the tumor 
burden is high, the S100B level in the serum rises. S100B is useful in the following 
situations:  
 
- Early detection of disease progression in tumor free patients à an elevation of 
S100 in comparison to the initial value indicates a new activity of the tumor. 
- Treatment monitoring and response à a decline of S100 is associated with a 
tumor mass reduction. 
- Estimation of the OS in patients with distant metastasis à patients with a 
value clearly over the reference range, have a poorer OS than patients with 
average values (46).  
 
LDH   
LDH (lactate dehydrogenase) is a ubiquitous cytoplasmatic enzyme in the human 
body and represents the key enzyme of the glycolysis as it catalyzes the turnover 
from lactate to pyruvate. As LDH is expressed in almost every human cell, its blood 
level increases with tissue damages of all kinds. An elevation of LDH can happen in 
the following diseases:  
 
- Tissue damage or hemolysis (e.g. trauma) 
- Heart muscle or liver damage (e.g. myocardial infarction) 
- Myopathy (e.g. myositis) 
- Malignant neoplasia (46) 
 
In solid tumors, including malignant melanoma, elevated LDH levels are associated 
with an impaired survival (47). Elevated serum levels of LDH strongly correlate with 
metastatic disease. In 2001, LDH was the first laboratory parameter being 
incorporated in the leading system of tumor staging in malignant melanoma, AJCC 
(American Joint Committee on Cancer) (32). In the current AJCC staging, patients 
with distant metastasis, independent of its localization, and additional elevated LDH 
are listed as M1c, as it is known that the prognosis of these patients is poorer (41).  
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In a current published study of 617 advanced melanoma patients (from randomized 
phase III clinical trials), treated with a combination of BRAF- (dabrafenib) and MEK 
inhibitor (trametinib), were retrospectively analyzed in terms of predictive factors for 
clinical outcome.  
It has been showed that patients with normal LDH levels had a substantial better 1- 
and 2-year OS and PFS in comparison to patients with LDH levels at least two times 
the upper limit of normal (48). However it is not known, whether elevated LDH levels 
are marker of aggressive disease or if it has a direct causative role in response to 
treatment or tumor growth (48). 
 
Recently, Frauchiger et al. suggested a significant negative impact of elevated LDH 
levels on OS in both BRAF mutated and wild type patients. With this findings they 
could confirm LDH as an BRAF independent marker for survival in advanced 
melanoma in their study (49).  
 
3.4.4. Pattern of Metastasis  
Overall, primary melanomas mostly metastasize to the regional lymph nodes, but 
approximately one third of them directly presents with metastasis at distant sites (24, 
50). The most common sites of distant metastasis are lymph node, skin, lungs, liver, 
brain and bone. Metastasis of the lungs, liver and brain are the most common causes 
of death in advanced MM patients (51, 52). Meier et al. showed that the localization 
of primary tumor is a strongly predictor of where metastasis would develop, based on 
a retrospective clinical trial of 466 patients. They suggested, that patients with 
primaries at the extremities or on the trunk most probable develop satellite or in-
transit metastasis, whereas tumors of the head and neck can develop in-transit, 
lymph node or directly present with distant metastasis (50).  
 
Furthermore, in another study with more than 1’100 stage IV melanoma patients, the 
site of distant metastasis was the only significant prognostic feature for clinical 
outcome. It was shown that non-visceral metastasis have the best survival, followed 
by lung metastasis and then all other visceral metastasis (32).  
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In a recent study, no difference in metastatic spread between BRAF mutant and 
BRAF wild type could be shown (49).  
 
3.5. Formulation of a Question 
In this retrospective study, we aimed to investigate the subgroup of advanced 
melanoma patients who suffered from rapidly progressive disease and died within 3 
months after stage IV diagnosis. We analyzed possible clinico-pathological factors, 
which might indicate a rapid disease progression in this minority of patients.  
 
Hypotheses:  
1) Melanomas, which metastasize hematogenous (stadium N0M1c), are more 
aggressive than lymphatic metastasizing melanoma. 
2) A high number of afflicted organs indicate an unfavorable outcome. 
3) Bone, brain or liver metastasis serve as poor prognostic factors.  
4) Lymph node and lung metastasis have a better prognosis than other visceral 
metastasis (M1a/M1b vs. M1c).   
 14 
4. Materials and Methods 
4.1. Patient Selection and Data Acquisition 
In this retrospective study we evaluated all stage IV metastatic melanoma patients 
being treated at the Dermatology Department of the University Hospital Zurich (USZ) 
during the period January 2008 - December 2014. Stage IV disease was defined 
according to the current American Joint Committee on Cancer (AJCC) staging 
system. Data were collected by reviewing patient’s electronic medical files in our 
clinical database KISIM. All patients who fulfilled the inclusion criteria were registered 
in the Melanoma Registry Table (MRT). At the time of analysis, the MRT contained 
422 patients, 322 of them were dead and 120 still alive. Treatment after the first 
distant metastasis as well as epidemiological, clinic-pathological, laboratory and 
molecular parameters for each patient were collected.  
 
Our cohort was divided in two groups according to the OS (Fig. 2). OS was defined 
as the time (in months) from diagnosis of the first distant metastasis to death/last 
follow up. Cut off of follow up data was defined as in September of 2016. The study 
group (SG) includes metastatic melanoma patients with an OS of 3 or less months 
and contained 23 patients. The control group (CG) contains the 50 patients with the 
best SR (range: 38.4 – 173.5 months). 
 
Fig. 2: Green = Study Group; Orange = Control Group 
All	  melanoma	  patients	  seen	  at	  the	  Dermatology	  Department	  of	  the	  USZ	  from	  2008	  -­‐	  2014	  
Stage	  IV	  patients	  (442)	  
OS	  ≤	  3	  months	  (23	  patients)	   3	  <	  OS	  <	  38.4	  	  months	  	  (369	  patients)	  	   OS	  ≥	  38.4	  months	  	  (50	  patients)	  
Stage	  I	  -­‐	  III	  Patients	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Furthermore, disease free survival (DFS) is defined as the length of time in months 
from the diagnosis of the primary tumor to first distant metastasis. For the T-staging, 
the Breslow index is divided in four subgroups: T1 = 0-1.0mm, T2 = 1.01-2.0 mm, T3 
= 2.01-4.0 mm, T4 > 4.0 mm. Normal LDH and S100 levels were defined as lower or 
equal to the reference cut-offs of 480 U/l and 0.2 ug/l, respectively, as defined by the 
normal ranges of the local laboratories. We divided the number of afflicted organs in 
two subgroups: >2 and ≤2. 
 
At the time of data cut-off, one patient of the CG was still in stage IIIC disease. One 
patient of the SG died from an apoplexy (ACM left). 
 
4.2. Definition of Baseline and Endpoints 
Primary endpoint of this study was to identify the patient group with rapidly 
progressive lethal melanoma and to determine differences in clinical characteristics 
and its prognostic implications. Secondary endpoints included differences in time to 
first distant metastasis between our SG and CG, and differences in OS with brain, 
liver or bone metastasis versus without between the SG and CG.  
 
4.3. Statistical Analysis 
Descriptive statistics are listed as percentages of total for categorical variables and 
ordinal variables and median for continuous variables. OS was estimated with the 
Kaplan-Meier survival curves. Univariate logistic regression was performed on all 
clinically relevant factors between SG and CG. A p-value less than 0.05 was deemed 
as statistically significant. Precise clinical information was only available in 47 
patients in our CG and these are the ones that were used for the statistical survival 
analyses.  
 
4.4. Ethics 
Local ethics committee approved written informed consent for tissue storage 
including retrospective analysis with collection of clinical / laboratory / histological 
information (KEK-ZH-Nr. 647, 800). 
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5. Results 
5.1. Patient Characteristics 
For the MRT, 442 AJCC Stage IV melanoma patients who received systemic 
treatment for the disease from January 2008 until December 2014 were gathered. 
170 (38.5%) were female, 272 (61.5%) were male. Median age at first diagnosis was 
57 years (range 13.4 – 91.7 years). At the time of the last follow-up in September 
2016, 120 (27.1%) patients were alive, 322 (72.9%) deceased. 
 
For all patients, histopathologic information such as melanoma subtype, localization 
of primary tumor and tumor thickness were available. The presence of ulceration was 
obtainable in 36.2% of the patients. LDH- and S100-levels were known in 66.7% and 
in 67.2% of the patients respectively.  
 
83 patients fulfilled the inclusion criteria for the study; from those 23 formed the SG 
and 50 the CG. 
 
All the laboratory parameters as well as patient’s characteristics are listed in Table 1.  
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Table 1: TT: targeted therapy, IT: immunotherapy, CNS: central nervous system, LDH: lactade 
dehydrogenase, SSM: superficial spreading melanoma, NMM: nodular melanoma, ALM: 
acrolentiginous melanoma, other*: polypoid, ex naevo, not classified 
! Study!Group! Control!Group!
Age$(Median)$ 60.8! 52.2!
$ ! !
Breslow! ! !
0.0191! 3!(13%)! 5!(10%)!
1.0192! 3!(13%)! 6!(12%)!
2.0194! 7!(30.4%)! 9!(18%)!
>4mm! 7!(30.4%)! 13!(26%)!
unknown! 3!(13%)! 17!(34%)!
$ ! !
CNS$Metastases$ ! !
no! 20!(87%)! 50!(100%)!
yes! 3!(13%)! 0!(0%)!
$ ! !
Bone$Metastases$ ! !
No! 9!(39.1%)! 44!(88%)!!
yes! 14!(60.9%)! 6!(12%)!
! ! !
Liver$Metastases$ ! !
No! 7!(30.4%)! 43!(86%)!
yes! 16!(69.6%)! 7!(14%)!
! ! !
Number$of$Metastases$ ! !
195! 0!(0%)! 40!(80%)!
6915! 1!(4.3%)! 3!(6%)!
>15! 22!(95.6%)! 7!(14%)!
! ! !
Number$of$afflicted$
organs$
! !
≤!2! 7!(30.4%)! 48!(96%)!!
>!2! 16!(69.6%)! 2!(4%)!
! ! !
N0M1c$ ! !
Yes! 2!(8.7%)! 2!(4%)!
no! 21!(91.3%)! 48!(96%)!
! ! !
M>Stadium$ ! !
M1a/b! 2!(8.7%)! 29!(58%)!
M1c! 21!(91.3%)! 20!(40%)!
M0! 0!(0%)! 1!(2%)!
! ! !
LDH$$ ! !
elevated! 17!(73.9%)! 1!(2%)!
normal! 6!(26.1%)! 23!(46%)!
unknown! 0!(0%)! 26!(52%)!
$ ! !
$ ! !
$ Study!Group! Control!Group!
S100$ ! !
elevated! 20!(87%)! 11!(22%)!
normal! 2!(8.7%)! 18!(36%)!
unknown! 1!(4.3%)! 21!(42%)!
! $ !
Mutation$status$ $ !
BRAF!mut! 9!(39.1%)! 27!(54%)!
NRAs!mut! 1!(4.3%)! 7!(14%)!
$$ ! !
Sex$ ! !
Female! 7!(30.4%)! 25!(50%)!
Male! 16!(69.6%)! 25!(50%)!
! ! !
Therapy$ ! !
IT! 4!(17.4%)! 13!(26%)!
TT! 5!(21.5%)! 12!(24%)!
IT!+!TT! 1!(4.3%)! 18!(36%)!
Chemo! 9!(39.1%)! 5!(10%)!
Chemo!+!TT! 2!(8.7%)! 0!(0%)!
! ! !
Ulceration$ ! !
No!! 6!(26.1%)! 9!(18%)!
Yes! 6!(26.1%)! 7!(14%)!
Unknown! 11!(47.8%)! 34!(68%)!
! ! !
Melanoma$Type$ ! !
SSM! 5!(21.7%)! 8!(16%)!
NMM! 7!(30.4%)! 10!(20%)!
ALM! 1!(4.3%)! 2!(4%)!
Desmoplastic! 0!(0%)! 1!(2%)!
Mucosal! 1!(4.3%)! 2!(4%)!
Choroidal! 0!(0%)! 2!(4%)!
Amelanotic! 0!(0%)! 4!(8%)!
Other*! 1!(4.3%)! 0!(0%)!
Unknown! 8!(34.7%)! 21!(42%)!
$ ! !
Localisation$ ! !
Acra! 1!(4.3%)! 2!(4%)!
Lower!Limb! 9!(39.1%)! 13!(26%)!
Upper!Limb! 1!(4.3%)! 6!(12%)!
Trunk! 5!(21.7%)! 12!(24%)!
Head/Neck! 4!(17.4%)! 7!(14%)!
Sinunasal! 1!(4.3%)! 1!(2%)!
Uveal! 0!(0%)! 2!(4%)!
Other!! 1!(4.3%)! 1!(2%)!
unknown! 1!(4.3%)! 6!(12%)!
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5.2. Study Group 
Patient’s characteristics and demographics 
In the SG, 7 (30.4%) patients were female and 16 (69.6%) were male, median age at 
first diagnosis was 60.8 years (range 29 – 81.1 years).  
 
Localization and type of primary melanoma 
The most common localization of the primary melanoma was the lower limb (39.1%), 
followed by the trunk (21.7%) and then head/neck (17.4%). One patient had a 
sinonasal melanoma, while one had a melanoma of an unknown primary. The most 
common melanoma subtype was NMM (30.4%), followed by SSM (21.7%). One 
patient was diagnosed with ALM (4.3%) and another with mucosal melanoma. In 8 
patients the melanoma type was unknown (34.8%).  
 
Breslow-index and ulceration 
The patient distribution was as follows: three (13%) patients were classified as T1, 3 
(13%) as T2, 7 (30.4%) T3 and 7 (30.4%) as T4. In 3 (13%) patients the Breslow 
index was unknown. In approximately 50% of the patients the ulceration status was 
unknown. Six (26.1%) had a primary with ulceration, while 6 without.  
 
Laboratory parameters 
The LDH-level was elevated in 17 (73.9%) and was normal in 6 (26.1%) patients. 
The S100-level was elevated in 20 (87%). Two patients had normal S100 levels and 
of one the S100 was not available.  
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Fig. 3: Characteristics of the primary melanoma and laboratory parameters of the 
SG. 
 
Mutation status of patient population 
Nine (39.1%) patients harbored a BRAF mutation, 10 (43.4%) were BRAF-wild type 
and in 4 (17.4%) the BRAF mutation status was unknown. One (4.3%) patient 
harbored a NRAS mutation and 15 (65.2%) were NRAS-wild type. The NRAS 
mutation status was not known in 7 (30.4%) of the patients (see Fig. 4).  
 
                
Fig. 4: Mutation status of the SG; left: NRAS mutation, right: BRAF mutation.   
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Disease free survival and overall survival  
The mean DFS was 38.6, the median 9.1 months (range 0 – 235.6 months). The 
mean OS was 2.1, the median 2.4 months (range 0.5 – 3.0 months). 
 
 
 
Fig. 5: DFS: Time from stage I to stage IV diagnosis in months. 
 
 
Fig. 6: Kaplan-Meier survival curve of SG and CG 
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Fig. 7: Forest Plot 
 
 
Distant metastasis 
At stage IV disease, 14 (60.9%) patients were diagnosed with bone metastasis. On 
the other hand, liver metastasis were detected in 16 (69.6%) patients. The majority of 
the patients did not have brain metastasis (20 without versus 3 with). 21 (91.3%) 
patients were diagnosed with N1-3M1 melanoma (according to AJCC), while only 2 
patients were diagnosed with N0M1. 16 (69.6%) patients had more than two afflicted 
organs at the time of stage IV disease, 7 (30.4%) had two or less afflicted organs. 2 
(8.7%) patients had an M1a or M1b stadium compared to 21 (91.3%) with M1c.  
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Fig. 8: Characteristics of distant metastasis when patients entered stage IV. 
Comparison of SG and CG.  
 
Initial treatment 
Nine (39.1%%) patients of the SG received chemotherapy as first treatment at time 
of stage IV disease. Five (21.7%) were treated with targeted therapy and four 
(17.4%) received immunotherapy. Two (8.7%) patients received chemotherapy 
combined with the multikinase inhibitor sorafenib (DTIC and sorafenib), one (4.3%) a 
combination of immunotherapy and targeted therapy, as at that time none of the new 
treatments were available. (One (4.3%) patient received chemotherapy in 
combination with darleukin (L19IL2, a human immunostimulatory antibody), and 
another one (4.3%) patient was treated with pasireotide (NCT01652547). 
 
5.3. Control Group 
Patient’s characteristics and demographics 
In the CG 25 (50%) were female and 25 (50%) were male, median age at first 
diagnosis was 52.2 years (range 18.9 – 72 years). 
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Localization and type of primary melanoma 
The most common localization of the primary melanoma was the lower limb (26%), 
followed by the trunk (24%), head/neck area (14%) and the upper limb (12%).  Two 
patients presented with an acral melanoma (4%), two with uveal and one with 
sinonasal. In 6 patients the localization was unknown (12%). The most common 
melanoma subtype was NMM (20%), followed by SSM (16%) and ALM (4%). Four 
patients were diagnosed with amelanotic (8%), two with mucosal (4%), two with 
choroidal (4%) and one with desmoplastic (2%) melanoma. In 21 patients the 
melanoma type was not classified (42%).  
 
Breslow-index and ulceration 
5 (10%) patients were classified as T1, 6 (12%) as T2, 9 (18%) T3 and 13 (26%) as 
T4. In 17 (34%) patients the Breslow index was unknown. In 7 (14%) patients the 
primary tumor carried ulceration, in 9 (18%) there was no ulceration noted. In 34 
(68%) patients the ulceration status was unknown.  
 
Laboratory parameters 
The LDH-level was elevated in 1 (2%), was normal in 23 (46%) and unknown in 26 
(52%) patients. The S100-level was elevated in 11 (22%), was normal in 18 (36%) 
and unknown in 21 (42%) patients.  
 
 
Fig. 9: Characteristics of the primary melanoma and laboratory parameters of the CG 
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Mutation status of patient population 
27 (54%) patients harbored a BRAF mutation and 22 (44%) were BRAF-wild type. In 
one patient (2%) and in 7 (14%), the BRAF and NRAS status was unknown 
respectively. 7 (14%) had a NRAS mutation and 36 (72%) were NRAS-wild type.  
 
                 
Fig. 10: Mutation status of the CG; left: NRAS mutation, right: BRAF mutation.   
 
Disease free survival and overall survival  
The mean DFS was 52.3, the median 37 months (range 0 – 207.9 months). The 
mean OS was 59.6, the median 73 months (range 38.4 – 173.5 months). 
 
Distant metastasis (Fig. 8)  
At stage IV disease, only 6 (12%) patients had bone metastasis. Liver metastasis 
were detected in only 7 (14%) patients, while 43 (86%) did not have any liver 
metastasis at this stage. None of the patients had brain metastasis at stage IV 
disease. AJCC stadium N1-3M1 was found in 48 patients (96%), N0M1 only in 2 
patients (4%). 2 (4%) patients had more than two afflicted organs at the entering of 
stage IV, 48 (96%) had two or less afflicted organs. 29 (58%) patients had an M1a or 
M1b stadium when entering stage IV in comparison to 20 (40%) patients who were in 
stadium M1c, 1 (2%) patient was still in stadium M0 (stage IIIC).  
 
Initial Treatment 
Most of the patients of the SG were initially treated with a combination of 
immunotherapy and targeted therapy (36%). 13 patients were treated with 
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immunotherapy (26%) and 12 with targeted therapy (24%) alone. 5 patients were first 
treated with chemotherapy (10%). One patient was treated within the NY-ESO-1 
(NCT01213472) another with chemotherapy (dacarbazine) and darleukin. 
 
5.4. Case Reports 
 
Case Report 1  
 
In July 2008, a 58-year-old patient presented at his family doctor with a pigmented 
interdigital skin lesion on his left foot, which he newly observed 1 month ago. 
Subsequently, the lesion was excised and a superficial spreading melanoma (SSM) 
with a Breslow thickness of 1.6 mm with no ulceration was diagnosed. The patient 
was referred to our department for a wide resection with 1 cm safety margins and 
sentinel lymph node biopsy (SNLB). The sentinel lymph node showed one 
micrometastasis (pT2apN1(sn1/1)M0). The tumor was BRAF and NRAS wild type. 
  
An inguinal lymphadenectomy was performed in November 2008. The histology 
report revealed 15 tumor-free lymph nodes. In January 2009, the patient presented 
with, dark blue nodules highly suspicious of in-transit and satellite metastasis next to 
lymphadenectomy scar. LDH- as well as S100-levels were considerably increased. 
The PET-CT scans (Fig. 11) showed metastatic disease with diffuse hepatic, a small 
bowl metastasis in the right lower abdomen and multiple splenic metastasis as well 
as one solitary bone metastasis in the thoracic vertebra 6. The patient was included 
in the Sora-study (NCT00794235), an investigator controlled pilot study of sorafenib 
(multi kinase inhibitor) and dacarbazin (cytostatic) and was treated within the study 
protocol for 53 days. Unfortunately he progressed and died 2.4 months after the 
diagnosis of the distant metastasis at the age of 59. 
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Fig. 11: PET-CT at stage IV of disease.   
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Case Report 2  
 
A 42-year-old patient observed a non-pigmented dermal papule on his left thigh in 
spring 2012. The lesion was initially interpreted as benign by a regional 
dermatologist. Three months later and after a minimal trauma, the lesion started to 
bleed which concerned the patient. He then presented at his family doctor, who 
excised the lesion with CO2-laser. The histology showed an ulcerative, nodular 
malignant melanoma with a Breslow thickness of 2.17 mm. The patient was referred 
to our department for the further management and underwent a wide resection with 
2cm safety margins and a SLNB. Upon positive SLNB, a left inguinal 
lymphadenectomy took place, which was clear. The patient harbored a BRAF 
mutation. He refused adjuvant immunotherapy with interferon due to possible 
adverse effects and was followed up according to high-risk protocol.  
 
PET-CT scans in January 2013 indicated suspect ileocolic enhancements. A 
colonoscopy showed polyps without malignancy. Unfortunately the patient 
progressed 4 months later with multiple lymph node metastasis (retroperitoneal, 
para-aortic, next to the right musculus psoas, iliac internal and external (Fig. 12)). 
The bone-marrow puncture, which was initiated due to thrombocytopenia, revealed 
malignant infiltration. A therapy with vemurafenib (BRAF inhibitor) was initiated. 
Unfortunately the patient progressed and died two weeks after the diagnosis of a 
distant metastasis at the age of 53.  
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Fig. 12: CT scans at Stage IV of disease. Above: free liquid in the 
pelvis. Below: multiple lymph node metastasis.  
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Case Report 3  
 
A 52-year-old patient with a past history of primary melanoma on her right upper arm 
completely excised in 2007, presented in February 2010 at her dermatologist, due to 
a hurtful scar at the site of the primary excision. Initially the scar was diagnosed as a 
keloid. The reddish firm lesion was highly suspicious of relapse, so the patient was 
referred to our department for resection, further treatment evaluation and staging. 
Histology showed a nodular malignant melanoma with a Breslow Index of 5.5mm. In-
transit metastasis was also discussed in the differential diagnosis. Upon positive 
SLNB, the patient underwent an axillar lymphadenectomy, which showed additionally 
another metastatic lymph node (pT4N2M0). Gene analysis showed a N-RAS 
mutation.  
 
Six months later, she progressed with a new liver metastasis (Fig. 13). At that time 
point, no further organs were affected. As the patient was B-RAF wild type, an 
inclusion in the Roche BRIM-3 study (NCT01006980) was not possible, so she was 
put on dacarbazin (alkylating chemotherapeutic agent). The patient completed 13 
cycles of mono-chemotherapy, and due to progression of the mediastinal lymph node 
metastasis an additional therapy with sorafenib (multi kinase inhibitor) was 
implemented. Shortly after start, the patient developed a maculopapulous drug 
exanthema, so the treatment was interrupted.  
 
CT-scan showed again disease progression in November 2011, with three new liver 
metastasis in segments II/V/VIII and progressive lymph node metastasis 
aortopulmonary, infracarinary and hilar. One month later, she started on ipilimumab 
with a mixed response after 4 cycles. She was then included in the Novartis-
CEMK162X2102 clinical trial (NCT01352273), an open 1b phase study, with a 
combination of BRAF (RAF265) and MEK (MEK162) inhibitor (July 2012). 
Unfortunately and shortly after treatment initiation, the therapy was stopped again 
due to PD. A palliative symptomatic irradiation of the mediastinal lymph nodes with 
39 Gray took place in October 2012. Due to further disease progression, she was 
treated with pembrolizumab in the MERCK MK-3475 study (NCT01704287). After six 
cycles (from March to June 2013), therapy was stopped because of progressive 
disease. A therapy with imatinib (protein kinase inhibitor) was implemented, again 
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without response. The patient died at the age of 55, 38.4 months after the diagnosis 
of a distant metastasis. 
 
 
Fig. 13: PET-CT at stage IV of disease.  
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6. Discussion 
The goal of our study was to analyze the group of patients with rapidly progressive 
lethal melanoma and to investigate their clinical characteristics and prognostic 
implications. To our knowledge, this is the first study to compare clinical 
characteristics of well-defined melanoma patients with short or long survival out of a 
large patient population (n=442). 
 
LDH and S100 levels are already known to be important prognostic factors in 
metastatic melanoma disease (46, 47). We demonstrated that patients of our cohort 
with elevated LDH and/or S100 level are more likely to be in the short survivor group 
with OR=17 and OR=1.82, respectively (Fig. 7). We confirmed the negative impact of 
elevated LDH/S100 levels on the OS of these subpopulations. 
 
Interestingly, more men are diagnosed with rapidly progressive melanoma, 
representing 69.6% of our SG. This finding correlates with Crocetti’s recent 
statement, that female gender has a considerable protective effect on the mortality of 
malignant melanoma, though the reasons are still unknown (27). Possibly 
contributing to the women’s better survival, is our speculation that men do not pay 
attention to their skin the same as women do and therefore go through fewer medical 
checkups at the dermatologist and present with more advanced disease. 
 
It is to be expected that patients with NMM are more likely to be in the short survivor 
group, since the NMM has the most aggressive growth pattern and it is diagnosed 
rather late due to the missing radial growth phase (36). Nevertheless, both in our SG 
as well as in our CG cohort NMM was the most common subtype (30.4% and 20%), 
followed by SSM (21.7% and 16%). The most frequent localization of the primary 
melanoma was, in both groups, the lower limb. There is no significant difference 
regarding BRAF/NRAS mutations in-between the SG and CG (see Fig. 4/10).  
 
Even though tumor thickness and ulceration status are strong prognostic factors and 
both part of the AJCC melanoma staging system (41), we do not have a significant 
higher rate of ulcerations or thick melanomas in our SG compared to the CG (see 
Table 1, Fig. 3/9). However, it has to be considered that these findings are biased by 
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the high quantity of unknown Breslow-index (34%) as well as ulceration status (68%) 
in the CG.  
 
Our hypothesis, that patients with a direct hematogenous metastatic spread with no 
lymph node involvement are more likely to be part of the short survivor group could 
not be confirmed. There were too few patients with N0M1 stage in each group (SG: 
8.7% versus CG: 4%), that none safe interpretation can be made. Nevertheless, the 
finding of Pleiss et al. speaks against our hypothesis. In this small study and among 
others, the 5-year survival of N1M0 versus N0M1 stage patients was investigated. 
They came to the result that N0M1 had better 5-year survival in comparison to N1M0 
patients (61%, p=<0.02 versus 45%, p=<0.01) (53). As we expected, patients with a 
high number of afflicted organs were more likely to be in the SG than in the CG. 
There are clearly more patients with bone or liver metastasis, when entering stage IV 
disease, in the SG compared to the CG (shown in Tab. 1 and Fig. 8). Patients with 
brain metastasis were only in the SG. Herewith, we could verify bone, liver and brain 
metastasis as poor prognostic factors.  Our assumption, that patients with lymph 
node and/or lung metastasis (= M1a/M1b) have a better prognosis than those with 
other visceral metastasis could also be confirmed. However, this result may be 
biased by the fact that patients with an elevated LDH level are counted in the M1c 
group besides the localization of their metastasis.  
 
Clear limitations to our study are the retrospective setting as well as the small 
number of patients in the CG and especially the SG.  
 
In conclusion, we identified a patient group with rapidly progressive melanoma in our 
institute. Based on the available clinical information we could confirm the negative 
prognostic factors such as elevated LDH and S100 levels, the male gender as well 
as the presence of bone, brain and liver metastasis at stage IV disease. Further 
immunohistochemical and molecular investigation is needed to fully understand the 
parameters, genetic or not, which implicate the rapidly progressive melanoma 
patients, as it seems that despite the new treatments there are still some patients, 
who die rapidly on their disease.   
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